<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762892</url>
  </required_header>
  <id_info>
    <org_study_id>raltegravir atazanavir naive</org_study_id>
    <nct_id>NCT00762892</nct_id>
  </id_info>
  <brief_title>Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients</brief_title>
  <acronym>RAN</acronym>
  <official_title>A Pilot Study--randomized, Prospective, Single Site Trial Evaluating Raltegravir vs. Atazanavir in Combination With Truvada® for the Treatment of Antiretroviral naïve HIV Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot that will evaluate two regimens for treating HIV infected patients that
      haven't been on treatment before. HIV/AIDS patients may have an increased risk of myocardial
      infarction and antiretroviral therapy used may contribute to this. We will evaluate
      virological, immunological and cardiovascular effects of two HIV treatment regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will check blood studies used to evaluate HIV patients response to therapy including CD4
      count and HIV viral load test. We will check routine safety labs done on HIV patients and
      also check homocysteine levels and creatine kinase level. We will evaluate homocysteine and
      IL6 levels at baseline, week 48, and week 96.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in CD4 Count at 48 Weeks</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Log HIV Viral Load at 48 Weeks</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipids at 48 Weeks</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Interleukin-6 (IL-6) at 48 Weeks</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Homocysteine at 6 Months</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Raltegravir in combination with truvada (tenofovir and emtricitabine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atazanavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir and truvada</intervention_name>
    <description>Raltegravir 400 mg po bid, truvada 1 tab q daily</description>
    <arm_group_label>Raltegravir</arm_group_label>
    <other_name>Truvada is tenofovir 300 mg and emtricitabine 200 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir, Norvir and Truvada</intervention_name>
    <description>Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily</description>
    <arm_group_label>Atazanavir</arm_group_label>
    <other_name>Truvada is tenofovir 300 mg and emtricitabine 200 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be HIV-1 positive and naïve to HIV therapy.

          -  Patients must plan to participate and be available for the trial for the 96-week study
             period.

          -  Patients followed at Thomas Street Clinic.

          -  Patients must be over 18 years old.

        Exclusion Criteria:

          -  Patients must not be pregnant or plan to become pregnant over the 96-week study
             period.

          -  Patients cannot be on a proton pump inhibitor.

          -  Patients cannot be undergoing treatment for active tuberculosis.

          -  Renal Insufficiency with a creatinine clearance &lt; 50 ml/min/1.73 m2 by the MDRD GFR
             calculation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanvir K Bell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT-Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Street Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://omicsonline.org/lipid-and-biomarker-differences-between-raltegravir-and-atazanavir-ritonavir-at-48-weeks-in-the-raltegravir-atazanavir-2155-6113.1000192.php?aid=11665</url>
    <description>open access journal</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <results_first_submitted>December 19, 2014</results_first_submitted>
  <results_first_submitted_qc>December 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 5, 2015</results_first_posted>
  <last_update_submitted>December 19, 2014</last_update_submitted>
  <last_update_submitted_qc>December 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Tanvir K. Bell, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>Integrase inhibitor</keyword>
  <keyword>Protease inhibitor</keyword>
  <keyword>Naive patients</keyword>
  <keyword>HIV disease</keyword>
  <keyword>Lipids</keyword>
  <keyword>Treatment Naïve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>approached patients HIV positive, naive to therapy, single site, English and Spanish speaking/writing.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir</title>
          <description>Raltegravir in combination with truvada (tenofovir and emtricitabine)
Raltegravir and truvada: Raltegravir 400 mg po bid, truvada 1 tab q daily</description>
        </group>
        <group group_id="P2">
          <title>Atazanavir</title>
          <description>Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
Atazanavir, Norvir and Truvada: Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarceration</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir</title>
          <description>Raltegravir in combination with truvada (tenofovir and emtricitabine)
Raltegravir and truvada: Raltegravir 400 mg po bid, truvada 1 tab q daily</description>
        </group>
        <group group_id="B2">
          <title>Atazanavir</title>
          <description>Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
Atazanavir, Norvir and Truvada: Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.7" spread="11"/>
                    <measurement group_id="B2" value="38.8" spread="10"/>
                    <measurement group_id="B3" value="39.8" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in CD4 Count at 48 Weeks</title>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Raltegravir in combination with truvada (tenofovir and emtricitabine)
Raltegravir and truvada: Raltegravir 400 mg po bid, truvada 1 tab q daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir</title>
            <description>Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
Atazanavir, Norvir and Truvada: Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Count at 48 Weeks</title>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192" spread="26"/>
                    <measurement group_id="O2" value="205" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipids at 48 Weeks</title>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Raltegravir in combination with truvada (tenofovir and emtricitabine)
Raltegravir and truvada: Raltegravir 400 mg po bid, truvada 1 tab q daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir</title>
            <description>Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
Atazanavir, Norvir and Truvada: Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipids at 48 Weeks</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="7.66"/>
                    <measurement group_id="O2" value="8.13" spread="11.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.50" spread="18.47"/>
                    <measurement group_id="O2" value="16.88" spread="40.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.58"/>
                    <measurement group_id="O2" value="-1.38" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.13" spread="7.54"/>
                    <measurement group_id="O2" value="5.88" spread="14.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Log HIV Viral Load at 48 Weeks</title>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Raltegravir in combination with truvada (tenofovir and emtricitabine)
Raltegravir and truvada: Raltegravir 400 mg po bid, truvada 1 tab q daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir</title>
            <description>Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
Atazanavir, Norvir and Truvada: Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Log HIV Viral Load at 48 Weeks</title>
          <units>copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.05" spread="0.28"/>
                    <measurement group_id="O2" value="-3.29" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Interleukin-6 (IL-6) at 48 Weeks</title>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Raltegravir in combination with truvada (tenofovir and emtricitabine)
Raltegravir and truvada: Raltegravir 400 mg po bid, truvada 1 tab q daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir</title>
            <description>Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
Atazanavir, Norvir and Truvada: Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Interleukin-6 (IL-6) at 48 Weeks</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.71" spread="1.63"/>
                    <measurement group_id="O2" value="-4.47" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Homocysteine at 6 Months</title>
        <time_frame>Baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir</title>
            <description>Raltegravir in combination with truvada (tenofovir and emtricitabine)
Raltegravir and truvada: Raltegravir 400 mg po bid, truvada 1 tab q daily</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir</title>
            <description>Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
Atazanavir, Norvir and Truvada: Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Homocysteine at 6 Months</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.83"/>
                    <measurement group_id="O2" value="0.10" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir</title>
          <description>Raltegravir in combination with truvada (tenofovir and emtricitabine)
Raltegravir and truvada: Raltegravir 400 mg po bid, truvada 1 tab q daily</description>
        </group>
        <group group_id="E2">
          <title>Atazanavir</title>
          <description>Atazanavir, low dose ritonavir, and truvada (tenofovir and emtricitabine)
Atazanavir, Norvir and Truvada: Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>MAI infection, multi-organ failure, death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations are the relatively small sample size and loss to follow-up. Medical records of patients that were lost to follow up was reviewed to ensure that no SAE occurred. We also attempted multiple times to contact patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Tanvir Bell, MD</name_or_title>
      <organization>UT Health Science Center Houston</organization>
      <phone>713-500-6759</phone>
      <email>Tanvir.K.Bell@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

